Related Experiment Video

Updated: May 12, 2026

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology
07:13

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology

Published on: February 3, 2011

13.1K

The User's Guide to Amivantamab

Danielle Brazel1, Janellen Smith2, Sai-Hong Ignatius Ou2

  • 1Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA.

Targeted Oncology
|February 4, 2025
PubMed

Insights

Amivantamab offers new treatment options for non-small-cell lung cancer (NSCLC) with specific EGFR exon20ins mutations. This review details its use, efficacy, and managing unique side effects for optimal patient benefit.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Epidermal growth factor receptor (EGFR) exon20ins mutations in non-small-cell lung cancer (NSCLC) confer resistance to traditional tyrosine kinase inhibitors.
  • Amivantamab is a novel therapy targeting these resistant mutations through multiple mechanisms, including immune cell recruitment.
  • Approved indications for amivantamab span frontline and later-line settings for EGFR exon20ins NSCLC, and combination therapies for EGFR-sensitizing mutations.

Purpose of the Study:

  • To provide a comprehensive review of amivantamab's mechanism of action, pharmacology, and clinical trial data.
  • To guide clinicians in managing the unique toxicities associated with amivantamab treatment.
  • To serve as a practical reference for healthcare professionals and researchers managing NSCLC patients.

Main Methods:

  • Review of published clinical trial data on amivantamab in NSCLC.
  • Analysis of amivantamab's pharmacological properties and mechanisms of action.
  • Synthesis of information on managing amivantamab-related side effects.

Main Results:

  • Amivantamab demonstrates efficacy in NSCLC with EGFR exon20ins mutations, approved in various settings.
  • The drug's unique mechanisms involve bypassing resistance mutations and engaging immune responses.
  • Management strategies for amivantamab-associated toxicities, linked to EGFR and MET pathway inhibition, are crucial.

Conclusions:

  • Amivantamab represents a significant advancement in treating specific NSCLC subtypes, particularly those with EGFR exon20ins mutations.
  • Effective management of amivantamab's side effects is essential for maximizing therapeutic benefits and patient outcomes.
  • This review provides valuable insights for clinicians and researchers involved in NSCLC targeted therapy.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

4.4K

Related Concept Videos

Affinity and Avidity01:41

Affinity and Avidity

Overview
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...